At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 347 enrolled
Drug / intervention
regadenoson +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Caffeine Intake on Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI) in Subjects Administered Regadenoson
In Brief
A Phase 3 clinical trial evaluating regadenoson, overencapsulated caffeine, and 2 other interventions for Coronary Artery Disease (CAD). Completed, enrolled 347 participants across 25 sites.
Detailed Summary
Observe whether the administration of caffeine prior to regadenoson will affect the interpretation of test results in subjects with coronary artery disease (CAD) undergoing SPECT MPI
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Artery Disease (CAD)
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 2009
Enrollment StartMar 2009
Primary CompletionJul 2010
TodayJul 2026
First PostedJan 22, 2009
Enrollment StartMar 24, 2009
Primary CompletionJul 15, 2010
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 17.4 years ago
Interventions
regadenosondrug
IV
overencapsulated caffeinedrug
oral
technetiumradiation
IV
placebodrug
oral